Vascular Complications with Chronic Myeloid Leukemia Therapy

Increased risk for venous and arterial complications was observed during long-term tyrosine kinase inhibitor therapy.

Targeting the chimeric BCR-ABL fusion protein with tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes in chronic-phase chronic myeloid leukemia (CML), with overall survival now approaching that of the general population. However, late complications of chronic daily therapy are not fully known.

Now, Swedish investigators have utilized the National Patient Registry to perform a retrospective analysis of cardiovascular events in 896 chronic-phase CML patients diagnosed between 2002 and 2012. All patients had received TKI therapy; 87.1% received imatinib, 26.9% received nilotinib, and 23.4% received dasatinib. Five age- and gender-matched controls from the registry served as comparators for each patient.

During a median follow-u…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Vascular Complications with Chronic Myeloid Leukemia Therapy

Topics

Reviewing Author